Associated virus-bacterial vaccine based on seasonal LAIV and S. pneumoniae chimeric peptide provide protection against post-influenza pneumococcal infection in mouse model
Severe influenza complications are often caused by Streptococcus pneumoniae infection, which presents the most common cause of community-acquired pneumonia. We evaluated in a mouse model an associated virus-bacterial vaccine based on seasonal live influenza vaccines (LAIV) and S. pneumoniae chimeric protein comprising flagellin (PSPF). Intranasal immunization of mice with a complex of trivalent LAIV and PSPF caused an increased release of early cytokines in the lungs of mice. The immunogenicity of LAIV and PSPF in the associated vaccine composition was sometimes decreased compared to each vaccine preparation alone. Nevertheless, only vaccination of mice with LAIV+PSPF significantly reduced lethality and the bacterial load in the lungs in a model of post-influenza bacterial pneumonia. The study of the interactions of influenza viruses with bacterial peptides is important during the development of associated virus-bacterial vaccines intended for the prevention of severe post-influenza bacterial complications.
| Medienart: |
E-Artikel |
|---|
| Erscheinungsjahr: |
2022 |
|---|---|
| Erschienen: |
2022 |
| Enthalten in: |
Zur Gesamtaufnahme - volume:13 |
|---|---|
| Enthalten in: |
Virulence - 13(2022), 1 vom: 19. Dez., Seite 558-568 |
| Sprache: |
Englisch |
|---|
| Beteiligte Personen: |
Desheva, Yulia [VerfasserIn] |
|---|
| Links: |
|---|
| Themen: |
Bacterial Vaccines |
|---|
| Anmerkungen: |
Date Completed 15.04.2022 Date Revised 15.04.2022 published: Print Citation Status MEDLINE |
|---|
| doi: |
10.1080/21505594.2022.2049496 |
|---|
| funding: |
|
|---|---|
| Förderinstitution / Projekttitel: |
|
| PPN (Katalog-ID): |
NLM337973105 |
|---|
| LEADER | 01000naa a22002652 4500 | ||
|---|---|---|---|
| 001 | NLM337973105 | ||
| 003 | DE-627 | ||
| 005 | 20231225235627.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 231225s2022 xx |||||o 00| ||eng c | ||
| 024 | 7 | |a 10.1080/21505594.2022.2049496 |2 doi | |
| 028 | 5 | 2 | |a pubmed24n1126.xml |
| 035 | |a (DE-627)NLM337973105 | ||
| 035 | |a (NLM)35266442 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a eng | ||
| 100 | 1 | |a Desheva, Yulia |e verfasserin |4 aut | |
| 245 | 1 | 0 | |a Associated virus-bacterial vaccine based on seasonal LAIV and S. pneumoniae chimeric peptide provide protection against post-influenza pneumococcal infection in mouse model |
| 264 | 1 | |c 2022 | |
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a ƒaComputermedien |b c |2 rdamedia | ||
| 338 | |a ƒa Online-Ressource |b cr |2 rdacarrier | ||
| 500 | |a Date Completed 15.04.2022 | ||
| 500 | |a Date Revised 15.04.2022 | ||
| 500 | |a published: Print | ||
| 500 | |a Citation Status MEDLINE | ||
| 520 | |a Severe influenza complications are often caused by Streptococcus pneumoniae infection, which presents the most common cause of community-acquired pneumonia. We evaluated in a mouse model an associated virus-bacterial vaccine based on seasonal live influenza vaccines (LAIV) and S. pneumoniae chimeric protein comprising flagellin (PSPF). Intranasal immunization of mice with a complex of trivalent LAIV and PSPF caused an increased release of early cytokines in the lungs of mice. The immunogenicity of LAIV and PSPF in the associated vaccine composition was sometimes decreased compared to each vaccine preparation alone. Nevertheless, only vaccination of mice with LAIV+PSPF significantly reduced lethality and the bacterial load in the lungs in a model of post-influenza bacterial pneumonia. The study of the interactions of influenza viruses with bacterial peptides is important during the development of associated virus-bacterial vaccines intended for the prevention of severe post-influenza bacterial complications | ||
| 650 | 4 | |a Journal Article | |
| 650 | 4 | |a Research Support, Non-U.S. Gov't | |
| 650 | 4 | |a Streptococcus pneumoniae | |
| 650 | 4 | |a early cytokines | |
| 650 | 4 | |a influenza infection | |
| 650 | 4 | |a mucosal vaccine | |
| 650 | 7 | |a Bacterial Vaccines |2 NLM | |
| 650 | 7 | |a Influenza Vaccines |2 NLM | |
| 650 | 7 | |a Peptides |2 NLM | |
| 650 | 7 | |a Vaccines, Attenuated |2 NLM | |
| 700 | 1 | |a Leontieva, Galina |e verfasserin |4 aut | |
| 700 | 1 | |a Kramskaya, Tatiana |e verfasserin |4 aut | |
| 700 | 1 | |a Losev, Igor |e verfasserin |4 aut | |
| 700 | 1 | |a Petkova, Nadezhda |e verfasserin |4 aut | |
| 700 | 1 | |a Rekstin, Andrey |e verfasserin |4 aut | |
| 700 | 1 | |a Suvorov, Alexander |e verfasserin |4 aut | |
| 773 | 0 | 8 | |i Enthalten in |t Virulence |d 2010 |g 13(2022), 1 vom: 19. Dez., Seite 558-568 |w (DE-627)NLM199668515 |x 2150-5608 |7 nnns |
| 773 | 1 | 8 | |g volume:13 |g year:2022 |g number:1 |g day:19 |g month:12 |g pages:558-568 |
| 856 | 4 | 0 | |u http://dx.doi.org/10.1080/21505594.2022.2049496 |3 Volltext |
| 912 | |a GBV_USEFLAG_A | ||
| 912 | |a GBV_NLM | ||
| 951 | |a AR | ||
| 952 | |d 13 |j 2022 |e 1 |b 19 |c 12 |h 558-568 | ||